Xencor, Inc. (XNCR) Q2 2025 10-Q Summary
Business Context and Reporting Period
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics for cancer and autoimmune diseases. This report covers the quarterly period ended June 30, 2025. The company operates as a single reportable segment and relies on collaboration, licensing, and milestone payments for revenue, as it has no internally developed products approved for commercial sale.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $43.6 million | $23.9 million | $76.3 million | $39.9 million |
| Net Loss (Attributable to Xencor) | $(30.8) million | $(67.3) million | $(79.2) million | $(140.8) million |
| Net Loss Per Share (Basic & Diluted) | $(0.41) | $(1.09) | $(1.07) | $(2.29) |
| Operating Expenses | $76.8 million | $79.3 million | $152.7 million | $149.9 million |
| Cash & Cash Equivalents | $44.4 million | (Balance Sheet Data) | ||
| Marketable Securities (Debt & Equity) | $399.4 million | |||
| Total Liquidity (Cash + Securities) | $443.8 million | (As of June 30, 2025) | ||
| Liabilities (Royalty Sales) | $145.0 million | (Current + Long-term) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 82% year-over-year for the quarter and 91% year-over-year for the six-month period. This was driven primarily by milestone payments and royalties from key partners.
- Milestone Payments:
- Incyte: A $25.0 million regulatory milestone was recognized in Q2 2025 following FDA approval of a supplemental biologics license application for Monjuvi (tafasitamab). An additional $12.5 million milestone was recognized in Q1 2025.
- Vir Bio: A $2.0 million milestone was recognized in Q2 2025 upon initiation of a Phase 3 study for tobevibart.
- Royalty Revenue: Royalties from Alexion (Ultomiris) increased to $16.8 million in Q2 2025 from $13.9 million in Q2 2024.
- Asset Impairment: The company recorded asset impairment charges of $1.9 million in Q2 2025 and $6.7 million YTD 2025, related to pausing development of certain programs. This compares to $20.4 million in impairment charges YTD 2024.
- Investment Gains: Net gains on marketable equity securities were $5.0 million in Q2 2025, compared to a loss of $12.0 million in Q2 2024.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current financial resources ($663.8 million in cash and marketable securities as of June 30, 2025) are sufficient to fund operations through at least the next twelve months. The company expects existing resources to fund operations into 2028, contingent on milestone receipts.
- Pipeline Updates:
- XmAb942: Phase 2b study in ulcerative colitis (XENITH-UC) expected to initiate in Q3 2025.
- Plamotamab: Regulatory authorization received in Q2 2025 to initiate a Phase 1b/2a study in rheumatoid arthritis.
- XmAb657: First-in-human study planned for the second half of 2025.
- Internal Controls & Restatement: The company disclosed that disclosure controls and procedures were not effective due to material weaknesses. These weaknesses relate to the accounting treatment of proceeds from the sale of future royalties and the evaluation of tax legislation. These issues led to the restatement of financial statements for 2023 and the first three quarters of 2024. Remediation plans are underway.
- Legal Proceedings: Merus N.V. has sued Xencor alleging patent infringement regarding common light chain antibodies. Xencor has filed a motion to dismiss and an inter partes review seeking to invalidate the asserted patents.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025. The company is evaluating its impact but does not expect a material change to its effective tax rate due to a full valuation allowance on deferred tax assets.
Investor Verification Checklist
- Restatement Impact: Verify the specific adjustments made to prior periods due to the material weaknesses in internal controls regarding royalty sales accounting.
- Royalty Sale Liabilities: Review the assumptions used to estimate future royalty payments for the Ultomiris and Monjuvi royalty sale agreements, which are recorded as debt liabilities totaling $145.0 million.
- Milestone Certainty: Assess the probability of future milestone payments from Incyte and Vir Bio, which are critical to the company's extended liquidity runway into 2028.
- Patent Litigation: Monitor the status of the Merus N.V. lawsuit and the inter partes review proceedings, as an adverse outcome could impact the company's core technology platform.
- Cash Burn Rate: Analyze the net cash used in operating activities ($52.6 million YTD 2025) against the current cash balance to validate the "into 2028" funding projection.